Literature DB >> 24704024

Methylation-associated silencing of microRNA-34b in hepatocellular carcinoma cancer.

Kaipeng Xie1, Jibin Liu2, Jiaping Chen1, Jing Dong1, Hongxia Ma1, Yao Liu1, Zhibin Hu3.   

Abstract

MicroRNAs (miRNAs) can act as oncogenes or tumor-suppressor genes in human cancers including HCC. Previous studies have identified miR-34 family as an important component of the tumor suppressor network during carcinogenesis. In this study, we investigated the methylation status of miR-34 family in HCC tumor and adjacent non-tumor tissues using methylation-specific PCR (MSP). The methylation frequencies of miR-34a and miR-34b/c were 72.1% (31/43) and 79.1% (34/43) in HCC tissues, which were significantly higher than that in the adjacent non-tumor tissues (P < 0.05), respectively. The results were validated by bisulfite sequencing PCR (BSP). Quantitative reverse transcription polymerase chain reaction (RT-PCR) analysis showed that the expression of miR-34a and miR-34b was significantly down-regulated in HCC tissues compared with adjacent non-tumor tissues (P < 0.05). Moreover, the expression of miR-34b was inversely correlated to CpG island methylation in tumor tissues, but not for miR-34a. In summary, our results suggest that DNA methylation may be involved in the inactivation of miR-34b in HCC.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Hepatocellular carcinoma; Methylation; miR-34a; miR-34b/c

Mesh:

Substances:

Year:  2014        PMID: 24704024     DOI: 10.1016/j.gene.2014.03.059

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  27 in total

Review 1.  Understanding the CREB1-miRNA feedback loop in human malignancies.

Authors:  Ya-Wen Wang; Xu Chen; Rong Ma; Peng Gao
Journal:  Tumour Biol       Date:  2016-04-09

Review 2.  Noncoding RNA as therapeutic targets for hepatocellular carcinoma.

Authors:  Joseph George; Tushar Patel
Journal:  Semin Liver Dis       Date:  2015-01-29       Impact factor: 6.115

3.  The deterministic role of 5-mers in microRNA-gene targeting.

Authors:  Martin Hart; Fabian Kern; Christina Backes; Stefanie Rheinheimer; Tobias Fehlmann; Andreas Keller; Eckart Meese
Journal:  RNA Biol       Date:  2018-05-11       Impact factor: 4.652

4.  Epigenetic Silencing of miRNA-34a in Human Cholangiocarcinoma via EZH2 and DNA Methylation: Impact on Regulation of Notch Pathway.

Authors:  Hyunjoo Kwon; Kyoungsub Song; Chang Han; Jinqiang Zhang; Lu Lu; Weina Chen; Tong Wu
Journal:  Am J Pathol       Date:  2017-10       Impact factor: 4.307

5.  Identification of coordinately regulated microRNA-gene networks that differ in baboons discordant for LDL-cholesterol.

Authors:  Genesio M Karere; Jeremy P Glenn; Shifra Birnbaum; Roy Garcia; John L VandeBerg; Laura A Cox
Journal:  PLoS One       Date:  2019-03-15       Impact factor: 3.240

6.  Upregulated expression of miR-106a by DNA hypomethylation plays an oncogenic role in hepatocellular carcinoma.

Authors:  Renshun Yuan; Qiaoming Zhi; Hong Zhao; Ye Han; Ling Gao; Bin Wang; Zhongyang Kou; Zhaoji Guo; Songbing He; Xiaofeng Xue; Hao Hu
Journal:  Tumour Biol       Date:  2014-12-16

Review 7.  Non-Coding RNAs in Primary Liver Cancer.

Authors:  Michele Ghidini; Chiara Braconi
Journal:  Front Med (Lausanne)       Date:  2015-06-04

Review 8.  The p53/microRNA connection in gastrointestinal cancer.

Authors:  Matjaz Rokavec; Huihui Li; Longchang Jiang; Heiko Hermeking
Journal:  Clin Exp Gastroenterol       Date:  2014-09-30

9.  RBMMMDA: predicting multiple types of disease-microRNA associations.

Authors:  Xing Chen; Chenggang Clarence Yan; Xiaotian Zhang; Zhaohui Li; Lixi Deng; Yongdong Zhang; Qionghai Dai
Journal:  Sci Rep       Date:  2015-09-08       Impact factor: 4.379

10.  An integrative analysis of meningioma tumors reveals the determinant genes and pathways of malignant transformation.

Authors:  José Carlos Iglesias Gómez; Adrián Mosquera Orgueira
Journal:  Front Oncol       Date:  2014-06-23       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.